Skip to main content

Table 3 Treatment responses in patients treated with artesunate/amodiaquine, artemether/lumefantrine and dihydroartemisinin/piperaquine in Tanzania: PCR corrected

From: Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania

Year

Drug/site

N

Excluded/lost

Re-infection

Uknown

LCF

LPF

ACPR

Kaplan–Meier

n (%)

n (%)

n (%)

% (95% CI)

% (95% CI)

% (95% CI)

% (95% CI)

2011

ASAQ

 Ujiji

73

8 (11.0)

12 (16.4)

3 (4.1)

0 (0.0–7.1)

2 (0.1–10.6)

98 (89.4–99.9)

98.3 (88.8–99.8)

 Kibaha

29

4 (13.8)

NA

NA

0 (0.0–13.7)

0 (0.0–13.7)

100 (86.3–100)

100

AL

 Muheza

32

2 (6.3)

0

1 (3.1)

0 (0.0–11.9)

0 (0.0–11.9)

100 (88.1–100)

100

2012

AL

 Chamwino

26

3 (11.5)

0

0

0 (0.0–14.8)

4.3 (0.1–21.9)

95.7 (78.1–99.0)

95.7 (72.9–99.4)

 Kyela

44

8 (18.2)

3 (6.8)

2 (4.5)

6.5 (0.8–21.4)

3.2 (0.1–16.7)

90.3 (74.2–98.0)

91.5 (75.9–97.2)

 Nagaga

62

23 (37.1)

NA

NA

0 (0.0–9.0)

0 (0.0–9.0)

100 (91.0–100)

100

2015

AL

 Kyela

80

16 (20.0)

3 (3.8)

1 (1.3)

0 (0.0–6.0)

0 (0.0–6.0)

100 (94.0–100)

100

DHA-PQ

 Rufiji

82

10 (12.2)

0

1 (1.2)

0 (0.0–5.1)

0 (0.0–5.1)

100 (94.9–100)

100

  1. Unknown unknown based on PCR analysis, LCF late clinical failure, LPF late parasitological failure, ACPR adequate clinical and parasitological response, ASAQ artesunate/amodiaquine, AL artemether/lumefantrine, DHAPQ dihydroartemisinin/piperaquine